Today we announced FDA clearance of the INDs for our two lead programs, SRF617 and SRF388, for which we are executing plans to initiate Phase 1 clinical trials. Full details in today’s press release here: https://t.co/HXeRkeHpZF
Today we announced FDA clearance of the INDs for our two lead programs, SRF617 and SRF388, for which we are executing plans to initiate Phase 1 clinical trials. Full details in today’s press release here: https://t.co/HXeRkeHpZF